Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00513175 · ClinicalTrials.gov registry record
Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia
A clinical trial, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 44
- Enrollment target
NCT00513175 is a clinical trial that has completed, run by University of California, San Francisco. The registered enrollment target is 44 participants.
The verdict
NCT00513175 has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 44 participants
- Enrollment target
Study Summary
The primary objective of this study is to examine transplant related mortality (TRM) at 100 days \<30%. A TRM of \>50% is considered unacceptable. This study also seeks a TRM at 12 months that is \<50%, engraftment \>90% (defined as donor cells \>80% at 6 months), and 1 year overall survival \>50%.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2001-10 |
| Est. Completion | 2007-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00513175
The ClinicalTrials.gov registry entry for NCT00513175 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00513175 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00513175 about?
NCT00513175 is a clinical study titled "Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia". The primary objective of this study is to examine transplant related mortality (TRM) at 100 days \<30%. A TRM of \>50% is considered unacceptable. This study also seeks a TRM at 12 months that is \<50%, engraftment \>90% (defined as donor cells \>80% at 6 months), and 1 year overall survival \>50%.
What is the current status of trial NCT00513175?
This trial is currently completed. The enrollment target is 44 participants. The study started on 2001-10. Estimated completion is 2007-11.
Who is sponsoring clinical trial NCT00513175?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.